Healixa Inc.
EMOR · OTC
6/30/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.70 | 4.49 | 0.33 |
| FCF Yield | -2.12% | 0.00% | -0.11% | -0.33% |
| EV / EBITDA | 361.58 | -328.16 | 2,298.31 | -185.90 |
| Quality | ||||
| ROIC | -0.77% | 3.99% | -0.77% | 5.06% |
| Gross Margin | 69.01% | 12.60% | 69.01% | 6.77% |
| Cash Conversion Ratio | 2.96 | 1.34 | 0.39 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 383.59% | 934,492.84% | 967,344.65% | 885,054.41% |
| Free Cash Flow Growth | 0.00% | 0.00% | 16.90% | 55.97% |
| Safety | ||||
| Net Debt / EBITDA | 172.12 | -49.50 | 220.39 | -38.11 |
| Interest Coverage | 0.34 | 0.00 | 0.34 | -1.75 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,327.61 | -453.44 | -396.27 | -327.03 |